Merck Acquires CN201 from Curon for B-Cell Disease Treatment
On October 1, 2024, Merck announced its acquisition of CN201 from Curon Biopharmaceutical. CN201 is an experimental bispecific antibody in clinical trials, designed to target B-cell-related diseases such as autoimmune disorders and B-cell cancers. Currently, in Phase 1 and Phase 1b/2 clinical trials, CN201 shows promise in treating patients with relapsed or refractory non-Hodgkin's lymphoma and B-cell acute lymphocytic leukemia...
On October 1, 2024, Merck announced its acquisition of CN201 from Curon Biopharmaceutical. CN201 is an experimental bispecific antibody in clinical trials, designed to target B-cell-related diseases such as autoimmune disorders and B-cell cancers. Currently, in Phase 1 and Phase 1b/2 clinical trials, CN201 shows promise in treating patients with relapsed or refractory non-Hodgkin's lymphoma and B-cell acute lymphocytic leukemia. Preliminary data indicate that CN201 is well-tolerated and can lead to significant reductions in B-cell populations. This acquisition marks Merck's commitment to advancing innovative treatments for hematologic malignancies and autoimmune diseases, to enhance patient outcomes.
Merck's agreement with Curon grants them full global rights to CN201, reflecting a pre-tax charge of approximately $750 million, which will impact third-quarter non-GAAP results. Dr. Dean Y. Li, President of Merck Research Laboratories, emphasized the potential of CN201 to build on Curon's foundational work and expand its applications. The strategic acquisition highlights Merck's longstanding dedication to leveraging cutting-edge science to improve global health. With over 130 years of experience in developing medicines and vaccines, Merck remains focused on research and innovation to support long-term health and sustainability.
